A systemic route for drug loading to lymphatic phagocytes.
A systemic route for drug loading to lymphatic phagocytes.
复制标题
将药物装载至淋巴吞噬细胞的全身途径。
DOI：
10.1021/mp0499149
复制
发表时间：
2005
影响因子：
4.9
通讯作者：
Fischman,AJ
中科院分区：
文献类型：
--
作者：
Papisov,MI;Yurkovetskiy,A;Syed,S;Koshkina,N;Yin,M;Hiller,A;Fischman,AJ
淋巴结是许多类型病原体的主要萌发和增殖场所。在淋巴结组织中维持适当化疗剂的治疗水平对于治疗感染和癌症都是至关重要的。本研究旨在开发一种全身途径，使用淋巴结特异性纳米载体将药物负载于淋巴结吞噬细胞。后者组装成10−15 nm的颗粒，具有携带药物的核心和吞噬细胞归巢的聚（1→6）-α-d-葡萄糖基界面。研究了模型载体的体内生物学特性和微分布。纳米载体在淋巴结中的积累在中央淋巴结中达到30 - 35%剂量/g，并沉积在各种吞噬细胞群体中。后者包括携带从肺转移到淋巴结的吸入微粒的细胞。鉴于纳米载体能够运输和释放大量的各种药物物质，数据表明全身药物负载到淋巴吞噬细胞并通过药物释放到邻近细胞的可行性。关键词：淋巴结;吞噬细胞;药物递送;生物防御;炭疽;癌症
Lymph nodes are primary germination and proliferation sites for many types of pathogens. Maintaining therapeutic levels of appropriate chemotherapeutic agents in the lymph node tissue is critical for the treatment of both infection and cancer. This study was intended to develop a systemic route for loading lymph node phagocytes with drugs, using a lymph node specific nanocarrier. The latter is assembled as a 10−15 nm particle with a drug-carrying core and a phagocyte-homing poly(1→6)-α-d-glucose based interface. Biokinetics and microdistribution of the model carrier were investigated in vivo. Nanocarrier accumulation in lymph nodes reached 30−35% dose/g in central lymph nodes, with deposition in various phagocytic cell populations. The latter included cells harboring inhaled microparticles translocated to lymph nodes from the lungs. In view of the nanocarrier ability to transport and release significant amounts of various drug substances, the data suggests feasibility of systemic drug loading to lymphatic phagocytes and, through drug release, to the neighboring cells.Keywords: Lymph node; phagocyte; drug delivery; biodefense; anthrax; cancer